Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

FDA Approves Aficamten for Obstructive HCM

News Daily News

FDA Approves Aficamten for Obstructive HCM

December 29, 2025

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

December 15, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

July 14, 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

News Conference News ESC Heart Failure 2025

HELIOS-B: Additional Data Affirm Benefits of Vutrisiran for ATTR-CM

May 19, 2025

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

News Daily News

Vutrisiran, With the FDA’s Sign-off, Joins the Fray for ATTR-CM

March 21, 2025

Acoramidis Approved in Europe for ATTR Cardiomyopathy

News Daily News

Acoramidis Approved in Europe for ATTR Cardiomyopathy

Michael O'Riordan

February 12, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

Top Heart Failure News of 2024

News Daily News

Top Heart Failure News of 2024

December 31, 2024

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

News Daily News

FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR Cardiomyopathy

November 25, 2024

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

August 21, 2024

Evoque and Patisiran: A Tale of Two Regulatory Journeys

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

News Conference News THT 2024

Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF

Michael O'Riordan

March 08, 2024

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

June 05, 2023

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

News Features

Myriad Novel Devices Aim to Boost Decongestion in Acute HF

April 10, 2023

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

News Daily News

Angioedema Risk No Higher With ARNI Than With ACE Inhibitors, ARBs

January 23, 2023

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.